Observation of the Efficacy and Exploration of the Mechanism of Intrauterine Infusion of Concentrated Growth Factors for Treating Thin Endometrium Following Frozen Embryo Transfer

For many women trying to build a family through assisted reproduction, the journey hits a quiet but formidable wall: the lining of the womb is simply too thin. In medical terms, this is known as a thin endometrium. Think of the endometrium as the soft, nutrient-rich soil of a garden; if it is too shallow, a seed cannot take root, no matter how healthy the seed itself might be. When this lining measures seven millimeters or less at the critical moment of transfer, the chances of a successful pregnancy drop significantly, often falling well below the average success rate. For years, doctors have tried various methods to thicken this lining, from hormone therapies to physical stimulation, but the results have been inconsistent, and the treatments can be slow or difficult to tolerate. The search has been on for a way to reliably wake up the dormant tissue and encourage it to grow, offering a fresh start for those who have faced repeated disappointments.

A team of researchers at the Affiliated Hospital of Zunyi Medical University in China recently turned their attention to a substance that has shown promise in other areas of healing: concentrated growth factors. This material is derived from a patient's own blood. By spinning a small sample of blood in a centrifuge, doctors can separate out a gel-like layer rich in platelets and proteins that naturally signal the body to repair itself and grow new blood vessels. While similar substances have been used before, this specific type, known as concentrated growth factors, is prepared in a standardized way and forms a stable film that can stay in place longer. The researchers wanted to see if placing this gel directly inside the uterus could thicken the lining and improve the odds of pregnancy for women undergoing frozen embryo transfer, a procedure where embryos are thawed and placed in the uterus at a later date.

To find out, the team enrolled sixty women who had been diagnosed with a thin endometrium and were preparing for this type of transfer. They split the group into two equal parts. One group received the standard hormone treatment used to prepare the uterus, while the other group received the same hormones plus a single, gentle infusion of the concentrated growth factor gel into the uterus a few days after their period ended. The procedure involved a quick, careful insertion of the gel, which was then left to adhere to the uterine wall. The researchers then watched closely to see how the two groups fared, tracking everything from the thickness of the lining to the final outcome of the pregnancy. They also took a deeper look at the biology behind the scenes by conducting parallel experiments on rats, creating a model of a thin uterine lining and treating some of them with the same gel to observe how the tissue changed at a microscopic level.

The results offered a hopeful, though cautious, picture. In the women who received the growth factor treatment, the lining of the uterus showed signs of becoming more receptive to an embryo. On the day before the transfer, the doctors measured a specific score that combines the thickness, texture, and blood flow of the lining; the group with the gel scored significantly higher than the group without it. While the actual thickness of the lining and the volume of the uterine space did not show a statistically massive difference on paper, the overall quality of the lining appeared better. More importantly, the women who received the treatment saw higher rates of clinical pregnancy and live births compared to the control group. Specifically, sixty percent of the treated women achieved a clinical pregnancy, compared to roughly forty-seven percent in the control group, and the live birth rate was also higher, though the numbers were not large enough to declare a definitive statistical victory. The researchers noted that these improvements suggest the treatment is working, but they emphasized that larger studies are needed to confirm the finding with absolute certainty.

To understand why this might be happening, the researchers looked inside the uterine tissue of the rats they had treated. The animals that received the concentrated growth factor gel showed a clear thickening of the uterine lining and a noticeable increase in the number of glands, which are essential for nourishing an early pregnancy. When they examined the tissue under a microscope, they found that the gel had sparked a surge in the production of specific proteins that act as signals for building new blood vessels. In the treated rats, the levels of these growth signals were significantly higher than in the rats that did not receive the gel. This suggests that the gel works by waking up the body's own repair mechanisms, encouraging the growth of a richer network of tiny blood vessels that bring oxygen and nutrients to the uterine wall, effectively turning a sparse, thin layer into a more robust and welcoming environment for an embryo.

The study also highlighted the risks that remain for women with a thin lining, regardless of the treatment. Even with the improved outcomes, the women in the study who went on to have babies faced higher rates of certain complications, such as the placenta attaching too deeply to the uterine wall or bleeding after birth, compared to women with normal pregnancies. This serves as a reminder that while the treatment helps create a better starting point, the underlying challenges of a thin lining can still influence the later stages of pregnancy. The researchers concluded that infusing concentrated growth factors is a safe and promising way to improve the quality of the uterine lining and potentially increase the chances of a successful pregnancy. It appears to work by enhancing the blood supply and the overall health of the tissue, offering a new tool for doctors to help patients who have struggled with a lining that is too thin to support life.